Bangladesh

You are here:-Bangladesh
Bangladesh2018-11-11T11:55:57+00:00

TB remains a major public health problem in Bangladesh. The country ranks fourth in the world for both prevalences of TB and TB mortalities. It is estimated that about 81,000 people died in 2014 due to TB. In 2014, WHO reported 196,797 TB cases were notified to the national registry, 187,005 of which were new cases. Case notification rate of all forms of TB is low at 53%. Although there is no estimate of the prevalence of childhood TB, it is believed that childhood TB is severely under-diagnosed. MDR TB is an emerging threat in Bangladesh. According to WHO estimates, MDR-TB rate among all newly diagnosed cases is estimated at 1.4%, and among previously treated cases at 22%.

The TB CARE II Bangladesh project is a field support activity funded through the USAID TB CARE II Project, which is a cooperative agreement awarded to the URC led consortium in September 2010. The project, drawing on the Global Fund and the Government of Bangladesh expert resources, facilitates implementation of strategies to strengthen and expand TB DOTS, Programmatic Management of Drug Resistant TB (PMDT) programs, and health systems.

Aligned with National TB Control Programme strategic objectives and USAID/Dhaka strategic framework, the TB CARE II partnership’s activities complement the Global Fund and Government of Bangladesh efforts to strengthen all the components of Stop TB Strategy with a major emphasis on universal and early access to TB services, Programmatic Management of Drug Resistant TB (PMDT), and health systems strengthening.

The TB CARE II Project has made significant achievements in fighting against TB in Bangladesh. Key achievements include improved access to quality TB and MDR-TB Services, Laboratory Quality Assurance, Development of cPMDT Standard Operating Procedures, strengthening of social support services for MDR TB patients and strengthened support systems for the effective delivery of TB services at all levels.

TB CARE II mHealth Background

With the support of the USAID TB CARE II project, the National Tuberculosis Control Program (NTP) in Bangladesh initiated a Community-based Programmatic Management of Drug Resistance Tuberculosis (cPMDT) program to treat DR TB in 2011. The cPMDT program requires an initial 1-2 months of hospitalization for DR TB patients who are then transitioned to community-based care, allowing patients to receive DR TB treatment in their own community. After the introduction of cPMDT, a large number of DR TB patients are now being discharged after a short stay in the hospital. At the community level, these patients continue their treatment under the supervision of specially trained DR TB DOT (directly observed treatment) providers. Treatment for DR TB requires a complex drug regimen which needs to be maintained over years. The TB CARE II project has developed and introduced a TB mHealth application which is designed to support the DOT providers to ensure quality DOT, assist to quickly identify drug-related side effects and link patients to treatment, and above all assist in patient management by facilitating documentation of the management procedures. The mHealth application is a web-based monitoring tool which allows DOT providers and managers to keep track of services delivered and organize an electronic record of treatment history of the DR TB patients. This system is designed to get input from mobile devices used by the DOT providers (Smartphone) through a GPS enabled the mobile application.

News Related to TB and Bangladesh

ASSESSMENTS OF PROVIDERS ADHERENCE TO TB EVIDENCE BASED STANDARDS AND GUIDELINES IN BANGLADESH, ZAMBIA, AND KENYA

Despite the availability of TB guidelines/ standards in high burden TB countries, provider adherence remains a challenge. In most cases, provider adherence to guidelines is not a problem of individual performance, but a problem located in the health system itself – at the political, health services, community, and patient levels. Between 2011-2012, TB CARE II conducted multi-country studies in Bangladesh, Zambia, and Kenya to gather information on: (1) Knowledge

TB CARE II INTRODUCES HIGH LEVEL WORKSHOP TO CLOSE THE GAP ON DRUG-RESISTANT TB AMONG CHILDREN

Globally, few children with drug-resistant (DR) tuberculosis (TB) are identified, diagnosed, and given an appropriate treatment. Although advances have been made in critical high burden countries such as Bangladesh to increase access to quality care and treatment for DR TB, this disease is still considered largely to be a problem for adults, and children who are infected remain too often in the shadows, unable to access care. A child

NATIONAL GUIDELINES FOR THE MANAGEMENT OF TUBERCULOSIS IN CHILDREN

The Bangladesh National Tuberculosis Control Program (NTP), in partnership with USAID through the TB CARE II project, recently published a set of guidelines meant to assist in the diagnosis and management of TB in children. The guidelines come in response to the World Health Organization (WHO)’s Stop Tuberculosis (TB) Strategy.  The Strategy, which ultimately seeks to create a TB-Free world, promotes equal access to care for all people in an

REDUCING TB DELAYS: EVALUATING THE FREQUENCY AND CAUSES OF DELAYS IN BANGLADESH AND SWAZILAND

In 2011-2012, TB CARE II undertook a study to understand TB patients’ delays and inform the development of an integrated set of recommendations for TB program managers and service providers regarding the appropriateness of different strategies for reducing patient factor delays in accessing TB diagnostic and treatment services. The project, led by URC, developed a series of questionnaires which were field tested and applied to conduct field studies in

US AMBASSADOR TO BANGLADESH VISITS TB CARE II PROJECT SITE IN SYLHET

On January 20, 2013, US Ambassador to Bangladesh Mr. Dan W. Mozena visited the Teliapara Tea Garden in Sylhet to observe a community awareness and education session for the garden workers. The area around Sylhet is a traditional tea growing area; it is home to over 150 tea gardens, including three of the largest in the world both in area and production. The Health, Education, and Economic Development (HEED)

TB CARE II INTRODUCES HIGH LEVEL WORKSHOP TO CLOSE THE GAP ON DRUG-RESISTANT TB AMONG CHILDREN

Globally, few children with drug-resistant (DR) tuberculosis (TB) are identified, diagnosed, and given an appropriate treatment. Although advances have been made in critical high burden countries such as Bangladesh to increase access to quality care and treatment for DR TB, this disease is still considered largely to be a problem for adults, and children who are infected remain too often in the shadows, unable to access care. A child